In the search for a more integrative definition, the National Institute on Aging and the Alzheimer’s Association proposed the following: “AD refers to deposits of pathological Aβ and tau plaques, defined in vivo by abnormal biomarkers of Aβ and pathological tau (both criteria are necessary)”. The gene discussed is MAPT; the disease is Alzheimer disease.